Guardant Health Collaborates with Zephyr AI to Enhance Oncology Research

By combining Guardant’s diagnostics and data infrastructure with Zephyr’s AI-driven platform, the two companies aim to accelerate biomarker discovery, enhance therapy response monitoring, and support oncology drug development

California-based biotechnology company Guardant Health has collaborated with artificial-intelligence firm Zephyr AI to advance cancer research by leveraging real-world clinical and biological data in combination with machine-learning algorithms.

According to the partnership agreement, Guardant Health’s diagnostic analytics, DNA repository, and real-world data will be integrated with Zephyr AI’s large-scale AI and machine learning platform, which combines multimodal data, to generate insights into cancer biomarkers, supporting areas such as targeted therapy selection and drug response analysis.

Commenting on the partnership, Zephyr’s CEO Allen Chao said, “This collaboration represents the convergence of unmatched real-world data, leading-edge diagnostics, and cutting-edge machine learning to enable more precise, scalable, and impactful oncology solutions.”

“By working together, Guardant Health and Zephyr AI can supercharge discovery and development needed to transform cancer treatment and deliver on the promise of personalised medicines for cancer patients.”

The partnership aims to produce predictions of targeted cancer therapy responses that are validated using real-world data and incorporate biologically interpretable features to deliver actionable scientific insights.

By combining Guardant’s diagnostics and data infrastructure with Zephyr’s AI-driven platform, the two companies aim to accelerate biomarker discovery, enhance therapy response monitoring, and support oncology drug development.

"By combining our industry-leading molecular data with Zephyr AI’s advanced analytics platform, we’re taking another major step toward realizing the full potential of precision oncology," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health.

Recently, Guardant Health, Inc. announced that the U.S. FDA has approved its Guardant360 CDx blood test as a companion diagnostic for identifying advanced breast cancer patients with specific ESR1 mutations, which is expected to strengthen its position in precision cancer diagnostics.

Stay tuned for more such updates on Digital Health News